![]() |
市場調查報告書
商品編碼
1980621
血管閉合器械市場規模、佔有率、成長率及全球市場分析:按類型、應用和地區分類,並提供2026-2034年的洞察和預測Vascular Closure Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
全球血管閉合裝置(VCD)市場預計到2025年將達到21.1億美元,從2026年的22.8億美元成長到2034年的49.2億美元,2026年至2034年的複合年成長率將達到10.10%。北美在2025年將以43.30%的市場佔有率引領全球市場,這得益於其高額的醫療費用支出、先進的醫院基礎設施以及微創心血管手術的快速普及。
血管閉塞裝置用於控制導管介入手術(例如血管成形術、血管造影術和支架置入術)後動脈穿刺部位的出血。與手動壓迫止血相比,血管閉塞裝置在介入性心臟病學中越來越受歡迎,因為它們可以縮短止血時間、最大限度地減少併發症,並使患者能夠更快地下地行走。
根據美國國立衛生研究院(NIH)統計,美國每年進行超過一百萬例心臟導管介入手術。手術數量的增加顯著推動了全球對血管閉合裝置的需求。
新冠疫情的影響
2020年,由於擇期心血管手術延後和門診就診量減少,新冠肺炎疫情對市場造成了負面影響。隨著醫療系統優先應對疫情,介入性心臟病手術數量和對心室輔助裝置(VCD)的需求暫時下降。
然而,隨著2021年下半年限制措施的放鬆以及2022年手術數量的增加,市場已穩定復甦。到2023年,手術數量已恢復到疫情前水平,預計在2026年至2034年的預測期內將持續成長。
市場趨勢
先進產品介紹
一個值得注意的市場趨勢是開發先進的、可生物吸收的、無需縫合的閉合裝置,以最大限度地減少發炎、血腫和延遲止血等併發症。
例如,2021年7月,Vivasure Medical Ltd.推出了PerQseal Blue,這是一種完全可生物吸收、無需縫合的大口徑血管閉合裝置,用於經皮心血管手術。此類創新提高了手術安全性,並正推動這些裝置在全球的廣泛應用。
預計在預測期內,臨床試驗的增加、資金籌措投入的增加以及研發投資的擴大將加速技術進步。
市場成長要素
心臟介入手術數量增加
心血管疾病負擔日益加重是主要促進因素。根據全球疾病統計數據顯示,缺血性心臟疾病影響全球超過2.44億人。這一激增增加了對基於導管的診斷和治療程序的需求,直接推動了血管閉合裝置(VCD)的應用。
此外,根據經濟合作暨發展組織(OECD)的數據,包括墨西哥和加拿大在內的國家進行的血管成形術數量正在增加,從而促進了該技術在全球範圍內的發展。
經濟和臨床效益
與手動壓迫止血需要15分鐘或更長時間相比,使用血管閉合裝置(VCD)大約5分鐘即可止血。 VCD還能縮短住院時間,讓患者當天即可出院。
英國國家醫療服務體系(NHS)發布的一項研究表明,用血管阻斷裝置取代手動壓迫止血每年可節省高達560萬美元的費用。這些經濟效益是推動此類產品普及應用的主要動力。
抑制因子
儘管這些設備具有諸多優勢,但產品召回和安全隱患仍是亟待解決的挑戰。 2022年4月,美國食品藥物管理局(FDA)宣布召回Cardinal Health公司的CELT ACD設備,原因是血腫形成的風險。對無菌性和包裝缺陷的擔憂也是導致此次召回的原因,並對市場信心造成了負面影響。
此外,假性動脈瘤和動脈閉塞等併發症可能會限制其在某些臨床環境中的廣泛應用。
依產品類型
從市場區隔的角度來看,這些設備分為插入式設備和夾式設備。
按類型
通過通道區域
最終用戶
北美洲
北美持續引領市場,預計到 2025 年市場規模將達到 9.1 億美元。在美國,由於先進的醫療保健基礎設施和主要企業的強大影響力,預計到 2026 年,美國市場規模將達到 9.4 億美元。
歐洲
歐洲佔據第二大市場。預計到2026年,英國市場規模將達1億美元,德國市場預計到2026年將達到1.3億美元。
亞太地區
預計亞太地區從 2026 年到 2034 年將以最高的複合年成長率成長。受老年人口成長和心臟手術增加的心血管手術。
The global vascular closure devices (VCDs) market was valued at USD 2.11 billion in 2025 and is projected to grow from USD 2.28 billion in 2026 to USD 4.92 billion by 2034, registering a strong CAGR of 10.10% during 2026-2034. North America dominated the global market with a 43.30% share in 2025, supported by high healthcare expenditure, advanced hospital infrastructure, and rapid adoption of minimally invasive cardiovascular procedures.
Vascular closure devices are used to achieve hemostasis at arterial puncture sites following catheterization procedures such as angioplasty, angiography, and stent placements. Compared to manual compression, VCDs reduce hemostasis time, minimize complications, and enable early patient ambulation, making them increasingly preferred in interventional cardiology settings.
According to the National Institutes of Health, more than 1 million cardiac catheterization procedures are performed annually in the U.S. The growing number of such procedures significantly drives demand for vascular closure devices worldwide.
COVID-19 Impact
The COVID-19 pandemic negatively affected the market in 2020 due to postponement of elective cardiovascular procedures and reduced hospital visits. Healthcare systems prioritized pandemic management, leading to a temporary decline in interventional cardiology volumes and VCD demand.
However, with easing restrictions in late 2021 and increasing procedural volumes in 2022, the market recovered steadily. By 2023, procedure volumes returned to pre-pandemic levels, and sustained growth is expected throughout the 2026-2034 forecast period.
Market Trends
Introduction of Advanced Product Offerings
A prominent market trend is the development of advanced, bioresorbable, and sutureless closure devices to minimize complications such as inflammation, hematoma, and delayed hemostasis.
For example, in July 2021, Vivasure Medical Ltd. introduced PerQseal Blue, a fully bioresorbable, sutureless large-bore closure device for percutaneous cardiovascular procedures. Such innovations are enhancing procedural safety and expanding device adoption globally.
Increasing clinical trials, fundraising initiatives, and R&D investments are expected to accelerate technological advancements during the forecast period.
Market Growth Drivers
Rising Interventional Cardiology Procedures
The growing burden of cardiovascular diseases is a major driver. According to global disease statistics, ischemic heart disease affects over 244 million individuals worldwide. This surge increases demand for diagnostic and therapeutic catheter-based procedures, directly boosting VCD adoption.
Additionally, data from the Organisation for Economic Co-operation and Development shows rising angioplasty procedures across countries, including Mexico and Canada, reinforcing global procedural growth.
Economic and Clinical Benefits
VCDs provide hemostasis within approximately 5 minutes compared to more than 15 minutes with manual compression. They also reduce hospital stays and enable same-day discharge.
A study published by the National Health Service estimated potential annual savings of up to USD 5.6 million if closure devices replace manual compression. These economic advantages significantly strengthen product adoption.
Restraining Factors
Despite advantages, product recalls and safety concerns pose challenges. In April 2022, the U.S. Food and Drug Administration announced a recall of Cardinal Health's CELT ACD device due to hematoma formation risks. Sterility concerns and packaging defects also contribute to recalls, negatively affecting market confidence.
Additionally, complications such as pseudoaneurysm and arterial occlusion may restrict widespread adoption in certain clinical settings.
By Product Type
The market is segmented into plug-based and clip-based devices.
By Type
By Access Site
By End User
North America
North America generated USD 0.91 billion in 2025 and continues to dominate. The U.S. market is projected to reach USD 0.94 billion by 2026, driven by advanced healthcare infrastructure and strong presence of key players.
Europe
Europe holds the second-largest share. The UK market is estimated to reach USD 0.10 billion by 2026, while Germany is projected to reach USD 0.13 billion by 2026.
Asia Pacific
Asia Pacific is projected to grow at the highest CAGR during 2026-2034. China is estimated to reach USD 0.18 billion by 2026, Japan USD 0.05 billion, and India USD 0.13 billion, driven by rising geriatric populations and growing cardiac procedure volumes.
Competitive Landscape
Key players include Terumo Corporation, Abbott, Teleflex Incorporated, Haemonetics Corporation, Cordis, and Vivasure Medical Ltd.
In February 2024, Terumo expanded its manufacturing facility in Puerto Rico to meet rising demand for Angio-Seal VCDs, strengthening its global footprint.
Conclusion
The global vascular closure devices market is set to expand significantly from USD 2.11 billion in 2025 to USD 4.92 billion by 2034, supported by rising cardiovascular procedures, strong clinical benefits over manual compression, technological advancements, and favorable reimbursement policies. While product recalls and safety concerns present challenges, increasing procedural volumes, bioresorbable innovations, and expanding healthcare access-especially in Asia Pacific-will sustain long-term growth through 2034.
Segmentation By Product Type
By Type
By Access Site
By End-user
By Region